MedTrace Logo

ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

NCT00635284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-10-18

No results posted yet for this study

Summary

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.

Conditions

Interventions

DRUG

ABI-009

nab-rapamycin

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Ana M. Gonzalez, MD · M.D. Anderson Cancer Center

  • Sant P. Chawla, MD · Sarcoma Oncology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-01
Primary Completion
2011-06-01
Completion
2011-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635284 on ClinicalTrials.gov